LACHEN, Switzerland-Tuesday, May 29th 2018 [ AETOS Wire ] (BUSINESS WIRE) -- Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK. SubQ-8, currently under development, is a recombinant FVIII from a human cell line for subcutaneous administration. SubQ-8 is based on Octapharma’s human cell line-derived rFVIII product simoctocog alpha combined with a fragment of the von Willebrand Factor (VWF) protein, and harnesses the protective power of VWF in an innovative approach to facilitate transportation of FVIII into the circulation. Regular intravenous administration of FVIII poses a considerable burden to people with haemophilia A and their families. Alternative routes of administration may help to alleviate some of this burden and improve adherence to prophylaxis therapy. This symposium, entitled ‘Taking FVIII into the future: The development of subcutaneous rec ... Read more »

RUGGELL, Liechtenstein -Wednesday, May 30th 2018 [ AETOS Wire ] (BUSINESS WIRE)-- ORDERFOX.com is proud to announce a new ground-breaking collaboration with industry leader Autodesk; making visualization and procurement even easier. ORDERFOX.com is continuously focused on providing members a more efficient way to conduct daily business. With that always top-of-mind, ORDERFOX.com community members now have an even greater benefit - the integration of the Autodesk Forge platform viewing functionality. The Viewer now provides community members the ability to view and process potential business opportunities without additional software installed. In addition, as a benefit for existing and new users of Autodesk Fusion 360, Autodesk Inventor and Autodesk AutoCAD software, they will be able to access all of the features of the ORDERFOX.com platform within their chosen software. The Viewer integration into the global ORDERFOX.com platform brings vast benefits. Anyone who uploads computer ... Read more »

With the ICO, Aimedis aims to finance the global roll out of its blockchain- and AI-based eHealth platform, offering investors a unique chance to tap into the revolution of the way patients interact with doctors. AMSTERDAM & PRAGUE-Saturday, June 2nd 2018 [ AETOS Wire ] (BUSINESS WIRE)-- Dutch eHealth-provider Aimedis, creator of a blockchain and AI-based platform that allows patients and institutions to safely store and share health information, such as diagnoses, x-rays, blood screens etc., as well as it enables them to perform video consultations, or to get prescriptions for drugs online, now offers AIM, the cryptocurrency to be used for all kinds of services within its platform, to the public. By offering 300 million tokens with a nominal value of 0,12 US dollars per token, the doctor-led company strives to raise 36 million USD to finance further development of the platform and the international market roll-out, explains CEO Dr. Michael J. Kaldasch: “Following up on the succes ... Read more »

The OPTIMISMM study is the first Phase 3 Study to report findings for a triplet combination regimen in which 100% of patients have received prior lenalidomide therapy SUMMIT, N.J.-Saturday, June 2nd 2018 [ AETOS Wire ] (BUSINESS WIRE) -- Celgene Corporation (NASDAQ:CELG) today announced results from the OPTIMISMM study, a phase III, randomized, open-label, international clinical study of the investigational combination regimen of POMALYST® (pomalidomide), bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM) who had received at least one prior treatment including lenalidomide. The results were presented at the 54th Annual American Society of Clinical Oncology Scientific Sessions (ASCO) in Chicago, Illinois on June 1-5, 2018. OPTIMISMM evaluated the efficacy and safety of POMALYST/IMNOVID (pomalidomide) plus bortezomib and low-dose dexamethasone (PVd) versus bortezomib and low-dose dexamethasone (Vd) in patients with early RRMM (1-3 prior line ... Read more »